Skip to main content
. 2024 Sep 17;16(18):3182. doi: 10.3390/cancers16183182

Figure 3.

Figure 3

Total 10-year costs of treatment sequences by first two lines of treatment in patients with TP53 aberration. ACAL: acalabrutinib, ACAL + O: acalabrutinib in combination with obinutuzumab, CAD: Canadian dollars, CLB + O: chlorambucil in combination with obinutuzumab, IBRU: ibrutinib, V: venetoclax, VO: venetoclax in combination with obinutuzumab, VR: venetoclax in combination with rituximab. The black horizontal line represents the mean cost of all treatment sequences.